Jennifer Taubert

New Capabilities

Leading J&J's immunology commercial strategy

For two decades, the most effective treatments for moderate-to-severe psoriasis required needles — self-injected drugs or clinic infusions that many patients refused or abandoned. On March 18, 2026, the Food and Drug Administration (FDA) approved ICOTYDE, a once-daily pill that blocks the interleukin-23 (IL-23) receptor with the precision of an injectable biologic. In clinical trials of roughly 2,500 patients, about 70 percent achieved clear or almost clear skin at 16 weeks, with side effects within 1.1 percentage points of a placebo.

Updated Mar 18